U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H7N3
Molecular Weight 109.1292
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMIFAMPRIDINE

SMILES

NC1=CC=NC=C1N

InChI

InChIKey=OYTKINVCDFNREN-UHFFFAOYSA-N
InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)

HIDE SMILES / InChI
Molecular Formula C5H7N3
Molecular Weight 109.1292
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:22:23 UTC 2023
Edited
by admin
on Fri Dec 15 16:22:23 UTC 2023
Record UNII
RU4S6E2G0J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMIFAMPRIDINE
DASH   EMA EPAR   INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
AMIFAMPRIDINE [MI]
Common Name English
3,4 DIAMINOPYRIDINE
VANDF  
Systematic Name English
AMIFAMPRIDINE [ORANGE BOOK]
Common Name English
NSC-521760
Code English
amifampridine [INN]
Common Name English
PYRIDINE, 3,4-DIAMINO-
Systematic Name English
DAP
Common Name English
AMIFAMPRIDINE [MART.]
Common Name English
3,4-DIAMINOPYRIDINE
Systematic Name English
Amifampridine [WHO-DD]
Common Name English
AMIFAMPRIDINE [USAN]
Common Name English
3,4 DIAMINOPYRIDINE [VANDF]
Common Name English
3,4-DAP
Code English
DYNAMINE
Brand Name English
RUZURGI
Brand Name English
AMIFAMPRIDINE [EMA EPAR]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 56090
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
WHO-ATC N07XX05
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
WHO-VATC QN07XX05
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
FDA ORPHAN DRUG 51590
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
NDF-RT N0000192795
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
FDA ORPHAN DRUG 299909
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
NCI_THESAURUS C93038
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
FDA ORPHAN DRUG 43189
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
FDA ORPHAN DRUG 556516
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
EMA ASSESSMENT REPORTS FIRDAPSE (AUTHORIZED: LAMBERT-EATON MYASTHENIC SYNDROME)
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
Code System Code Type Description
DAILYMED
RU4S6E2G0J
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
ChEMBL
CHEMBL354077
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
RXCUI
2106338
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-220-9
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
FDA UNII
RU4S6E2G0J
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
NCI_THESAURUS
C82687
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
WIKIPEDIA
3,4-DIAMINOPYRIDINE
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
IUPHAR
8032
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
SMS_ID
100000092991
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
EVMPD
SUB28846
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
LACTMED
Amifampridine
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
MESH
C016361
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
MERCK INDEX
m1668
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY Merck Index
CAS
54-96-6
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
NSC
521760
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
USAN
BC-57
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
INN
8804
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
EPA CompTox
DTXSID6046715
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
PUBCHEM
5918
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
DRUG CENTRAL
4336
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
DRUG BANK
DB11640
Created by admin on Fri Dec 15 16:22:23 UTC 2023 , Edited by admin on Fri Dec 15 16:22:23 UTC 2023
PRIMARY
Related Record Type Details
Structure of AMIFAMPRIDINE
EXCRETED UNCHANGED
URINE
ARYLAMINE N-ACETYLTRANSFERASE 2
METABOLIC ENZYME -> SUBSTRATE
Structure of AMIFAMPRIDINE PHOSPHATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 3-N-ACETYL-AMIFAMPRIDINE
METABOLITE INACTIVE -> PARENT
Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of AMIFAMPRIDINE metabolism. Poor metabolizers, also referred to as “slow acetylators” (i.e., carriers of two reduced function alleles), have 3.5-to 4.5-fold higher Cmax, and 5.6-to 9fold higher AUC than normal metabolizers, also referred to as “fast/rapid acetylators” (i.e., carriers of two normal function alleles). In the general population, the NAT2 poor metabolizer phenotype prevalence is 40–60% in the White and African American populations, and in 10–30% in Asian ethnic populations (individuals of Japanese, Chinese, or Korean descent).
Related Record Type Details
Structure of AMIFAMPRIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966